They offer comprehensive clinical management tools and services in the field of molecular genomics, with a focus on oncology. Their portfolio includes cell-based and molecular genomic services, circulating tumor-based cancer screening assays, and a range of tests for breast and prostate cancers. Datar Genetics has been granted FDA designation for their accuracy in cancer diagnostics. They also provide multi-analyte molecular analysis platforms that identify effective drugs, allowing for advanced treatment strategies. With a team of highly qualified medical professionals and scientists, they aim to address the burden of non-communicable diseases through advanced genomic interrogation solutions across various domains, including oncology, cardiology, neurology, and more.